tradingkey.logo
tradingkey.logo
検索

Pacific Biosciences of California Inc

PACB
ウォッチリストに追加
1.120USD
-0.090-7.44%
終値 05/15, 16:00ET15分遅れの株価
347.87M時価総額
損失額直近12ヶ月PER

Pacific Biosciences of California Inc

1.120
-0.090-7.44%

詳細情報 Pacific Biosciences of California Inc 企業名

Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.

Pacific Biosciences of California Incの企業情報

企業コードPACB
会社名Pacific Biosciences of California Inc
上場日Oct 27, 2010
最高経営責任者「CEO」Henry (Christian O)
従業員数575
証券種類Ordinary Share
決算期末Oct 27
本社所在地1305 O'brien Drive
都市MENLO PARK
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号94025
電話番号16505218000
ウェブサイトhttps://www.pacb.com/
企業コードPACB
上場日Oct 27, 2010
最高経営責任者「CEO」Henry (Christian O)

Pacific Biosciences of California Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Christian O. Henry
Mr. Christian O. Henry
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.25M
+9.33%
Mr. Marshall L. Mohr, CPA
Mr. Marshall L. Mohr, CPA
Independent Director
Independent Director
132.82K
+17.18%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
132.82K
+17.18%
Mr. Randall S. (Randy) Livingston
Mr. Randall S. (Randy) Livingston
Independent Director
Independent Director
22.82K
--
Dr. Lucy Shapiro, Ph.D.
Dr. Lucy Shapiro, Ph.D.
Independent Director
Independent Director
22.82K
--
Mr. Bill Ericson ,J.D.
Mr. Bill Ericson ,J.D.
Independent Director
Independent Director
--
--
Ms. Kathy P. Ordonez
Ms. Kathy P. Ordonez
Independent Director
Independent Director
--
--
Mr. Mark Van Oene
Mr. Mark Van Oene
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Hannah A. Valantine, M.D.
Dr. Hannah A. Valantine, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher M. (Chris) Smith
Mr. Christopher M. (Chris) Smith
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Christian O. Henry
Mr. Christian O. Henry
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.25M
+9.33%
Mr. Marshall L. Mohr, CPA
Mr. Marshall L. Mohr, CPA
Independent Director
Independent Director
132.82K
+17.18%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
132.82K
+17.18%
Mr. Randall S. (Randy) Livingston
Mr. Randall S. (Randy) Livingston
Independent Director
Independent Director
22.82K
--
Dr. Lucy Shapiro, Ph.D.
Dr. Lucy Shapiro, Ph.D.
Independent Director
Independent Director
22.82K
--
Mr. Bill Ericson ,J.D.
Mr. Bill Ericson ,J.D.
Independent Director
Independent Director
--
--

収益内訳

通貨: USD更新時刻: Mon, Apr 6
通貨: USD更新時刻: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
Consumable revenue
81.94M
51.21%
Instrument revenue
53.82M
33.64%
Service And Other
24.25M
15.15%
地域別USD
会社名
収益
比率
North America
72.80M
45.50%
Europe (including the Middle East and Africa)
44.05M
27.53%
Asia Pacific
43.16M
26.97%
事業別
地域別
事業別USD
会社名
収益
比率
Consumable revenue
81.94M
51.21%
Instrument revenue
53.82M
33.64%
Service And Other
24.25M
15.15%

株主

更新時刻: Sun, May 10
更新時刻: Sun, May 10
株主統計
種類
株主統計
株主統計
比率
ARK Investment Management LLC
11.68%
SoftBank Group Corp
6.58%
BlackRock Institutional Trust Company, N.A.
6.53%
Vanguard Capital Management, LLC
4.11%
Geode Capital Management, L.L.C.
2.28%
他の
68.81%
株主統計
株主統計
比率
ARK Investment Management LLC
11.68%
SoftBank Group Corp
6.58%
BlackRock Institutional Trust Company, N.A.
6.53%
Vanguard Capital Management, LLC
4.11%
Geode Capital Management, L.L.C.
2.28%
他の
68.81%
種類
株主統計
比率
Investment Advisor
34.22%
Investment Advisor/Hedge Fund
10.46%
Hedge Fund
8.97%
Holding Company
6.58%
Research Firm
2.49%
Individual Investor
1.15%
Corporation
1.13%
Venture Capital
0.20%
Bank and Trust
0.17%
他の
34.63%

機関投資家保有株

更新時刻: Wed, Apr 1
更新時刻: Wed, Apr 1
報告期間
機関投資家数
保有株式数
比率
変動額
2026Q1
540
192.85M
62.12%
-19.48M
2025Q4
549
169.06M
56.00%
-65.22M
2025Q3
566
166.98M
55.32%
-97.69M
2025Q2
600
214.62M
71.52%
-110.62M
2025Q1
629
227.30M
75.82%
-104.21M
2024Q4
625
258.31M
94.32%
-61.55M
2024Q3
618
231.32M
84.94%
-85.30M
2024Q2
629
240.26M
88.29%
-64.03M
2024Q1
637
265.38M
97.57%
-38.04M
2023Q4
643
276.71M
103.53%
-9.49M
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
ARK Investment Management LLC
37.26M
12.34%
+6.34M
+20.50%
Dec 31, 2025
SoftBank Group Corp
20.45M
6.77%
--
--
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
20.30M
6.72%
+431.05K
+2.17%
Dec 31, 2025
Geode Capital Management, L.L.C.
7.08M
2.34%
+172.09K
+2.49%
Dec 31, 2025
Amova Asset Management Co., Ltd.
7.81M
2.59%
-868.98K
-10.01%
Dec 31, 2025
State Street Investment Management (US)
5.91M
1.96%
+2.58K
+0.04%
Dec 31, 2025
D. E. Shaw & Co., L.P.
4.44M
1.47%
+4.44M
--
Dec 31, 2025
Millennium Management LLC
4.34M
1.44%
-572.23K
-11.64%
Dec 31, 2025
Point72 (DIFC) Ltd
4.27M
1.41%
+1.81M
+73.65%
Sep 30, 2025
詳細を見る

関連ETF

更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
ARK Genomic Revolution ETF
2.3%
iShares Genomics Immunology and Healthcare ETF
1.31%
Invesco NASDAQ Future Gen 200 ETF
0.96%
Global X Genomics & Biotechnology ETF
0.69%
ARK Innovation ETF
0.58%
AXS Green Alpha ETF
0.58%
WisdomTree BioRevolution Fund
0.48%
Invesco RAFI US 1500 Small-Mid ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.08%
Invesco Nasdaq Biotechnology ETF
0.07%
詳細を見る
ARK Genomic Revolution ETF
比率2.3%
iShares Genomics Immunology and Healthcare ETF
比率1.31%
Invesco NASDAQ Future Gen 200 ETF
比率0.96%
Global X Genomics & Biotechnology ETF
比率0.69%
ARK Innovation ETF
比率0.58%
AXS Green Alpha ETF
比率0.58%
WisdomTree BioRevolution Fund
比率0.48%
Invesco RAFI US 1500 Small-Mid ETF
比率0.09%
ProShares Ultra Nasdaq Biotechnology
比率0.08%
Invesco Nasdaq Biotechnology ETF
比率0.07%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
KeyAI